预约演示
更新于：2025-06-24
Desloratadine
地氯雷他定
更新于：2025-06-24
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H19ClN2 |
InChIKeyJAUOIFJMECXRGI-UHFFFAOYSA-N |
CAS号100643-71-8 |
关联
121
项与 地氯雷他定 相关的临床试验TCTR20240427007
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Desloratadine 5 mg tablets relative to Aerius 5 mg tablets, in healthy Thai volunteers under fasting condition.
NCT06916884
Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine as Treatment in Patients With Allergic Rhinitis
CTR20243003
单中心、随机、开放、两周期交叉、单剂量空腹和餐后状态下的生物等效性试验
100 项与 地氯雷他定 相关的临床结果
登录后查看更多信息
100 项与 地氯雷他定 相关的转化医学
登录后查看更多信息
100 项与 地氯雷他定 相关的专利（医药）
登录后查看更多信息
1,699
项与 地氯雷他定 相关的文献（医药）2025-12-01European Journal of Trauma and Emergency Surgery
Increased use of damage control laparotomy for emergency small bowel or colon surgery: does it affect patient outcomes?
Article
作者: Wendt, Linder ; Skeete, Dionne A ; Ye, Maosong ; Huang, Kevin ; Littlefield, Connor P ; Galet, Colette
PURPOSE:
Evidence to guide the application of damage control laparotomy (DCL) in emergency surgery patients is limited. We assessed whether DCL use for emergent small bowel or colon surgery increased over time and its impact on outcomes. We hypothesized that DCL would be utilized more often in patients with significant comorbidities or septic shock with improved outcomes.
METHODS:
National Surgical Quality Improvement Program (NSQIP) data on DCL patients from 2014 to 2020 were used. Endpoints were incidence of DCL, in-hospital mortality, hospital length of stay (LOS), complications, and 30-day readmission over time. P-values < 0.05 were considered statistically significant.
RESULTS:
DCL incidence increased over time (OR = 1.07 [1.05-1.08], p < 0.001). Presence of pre-operative septic shock increased over the years (OR = 1.04 [1.01-1.07], p = 0.007). Mortality, readmission, and post-operative septic complications did not change over the study period. Average LOS significantly decreased over time (OR = 0.93 [0.92-0.95], p < 0.001).
CONCLUSION:
The odds of a surgeon using DCL increased by 7% each year. Although pre-operative septic shock incidence increased, LOS decreased over time while mortality remained unchanged.
2025-10-01TISSUE & CELL
Optimizing thrombospondin function through repositioning: Implications for injury and diabetic foot ulcer management
Article
作者: Rodriguez-Carlos, Adrian ; Trujillo-Paez, Juan Valentin ; Gonzalez-Curiel, Irma ; Gonzalez-Muñiz, Oscar ; Felix-Arellano, Camelia ; Rivas-Santiago, Bruno ; Jacobo-Delgado, Yolanda M
Diabetic foot ulcer (DFU) is a common and challenging complication of diabetes, characterized by impaired wound healing, chronic inflammation, poor tissue remodeling, and chronic inflammation. Thrombospondin 1 (TSP1) and thrombospondin 4 (TSP4) are key extracellular matrix proteins involved in wound healing. This study aimed to assess the levels and propose inducers of TSP1, TSP4, and SOD3 in diabetic foot ulcer. In this study, we first evaluated the expression of TSP1, TSP4, and superoxide dismutase 3 (SOD3) in DFU tissues using real-time PCR and immunohistochemistry. In DFU tissues using real-time PCR we found that TSP-4 expression was significantly reduced and confirmed by immunohistochemistry. TSP1 expression did not show similar alterations. Additionally, while SOD3 expression was decreased at the mRNA level in the diabetic population, no changes were observed in the protein levels by immunohistochemistry. To explore potential therapeutic approaches, we performed pharmacological repositioning and identified three drugs riboflavin, desloratadine, and chenodeoxycholic acid that selectively increased TSP-4 expression. These findings suggest that riboflavin, desloratadine, and chenodeoxycholic acid may promote wound healing in DFU by specifically upregulating TSP4, potentially enhancing tissue remodeling and angiogenesis.
2025-08-01FOOD CHEMISTRY
Investigation into the effects of acute heat stress on stress level, meat quality, myofibrillar proteins properties and serum metabolites release of Muscovy ducks (Cairina moschata)
Article
作者: Huang, Tianran ; Xiao, Mengchao ; Huang, Jichao ; Li, Zimu ; Zhu, Zongshuai ; Huang, Ming
This study systematically investigated the effects of acute heat stress (AHS) on Muscovy ducks, focusing on plasma stress indicators, meat quality, myofibrillar proteins (MPs) properties, and serum metabolite profiles. AHS significantly elevated stress level, impairing meat quality, as evidenced by higher L* value, shear force, drip loss, and cooking loss (P < 0.05). It also induced MPs oxidation and aggregation, reflected by elevated carbonyl content, turbidity, zeta potential, and particle size. MPs structural alterations were confirmed by fluorescence quenching and increased exposure of hydrophobic groups. Correlation analysis revealed strong associations between physicochemical changes and MPs oxidation. Metabolomic analysis identified 161 and 105 differential metabolites in the CON vs. LS and CON vs. SS comparisons, respectively, involving 25 metabolic pathways related to energy, amino acids, and fatty acids. These findings provide novel insights into the molecular pathways of AHS-induced meat quality deterioration and reveal potential intervention timing for the poultry industry.
100 项与 地氯雷他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 皮炎 | 日本 | 2016-09-28 | |
| 皮炎 | 日本 | 2016-09-28 | |
| 湿疹 | 日本 | 2016-09-28 | |
| 湿疹 | 日本 | 2016-09-28 | |
| 瘙痒 | 日本 | 2016-09-28 | |
| 常年性变应性鼻炎 | 澳大利亚 | 2003-05-28 | |
| 慢性荨麻疹 | 美国 | 2002-02-08 | |
| 季节性过敏性鼻炎 | 美国 | 2001-12-21 | |
| 过敏性鼻炎 | 欧盟 | 2001-01-15 | |
| 过敏性鼻炎 | 冰岛 | 2001-01-15 | |
| 过敏性鼻炎 | 列支敦士登 | 2001-01-15 | |
| 过敏性鼻炎 | 挪威 | 2001-01-15 | |
| 荨麻疹 | 欧盟 | 2001-01-15 | |
| 荨麻疹 | 冰岛 | 2001-01-15 | |
| 荨麻疹 | 列支敦士登 | 2001-01-15 | |
| 荨麻疹 | 挪威 | 2001-01-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 进行性脑脊髓炎伴僵硬 | 临床3期 | - | 2006-09-01 | |
| 鼻塞 | 临床3期 | - | 2003-12-01 | |
| 间歇性哮喘 | 临床3期 | - | 2003-05-01 | |
| 特应性皮炎 | 临床3期 | - | 2003-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 积极 | 2020-02-15 | |||
临床3期 | 449 | (Desloratadine) | 糧鹹憲鹹蓋廠製壓糧積(觸壓積網積蓋築鑰觸醖) = 夢壓範廠鬱遞膚網築鬱 選範襯廠築遞構願廠艱 (醖廠鏇鹹壓築糧齋夢壓, 顧鹽鬱壓鑰觸製鑰鏇鑰 ~ 鹹蓋遞構憲範築範襯構) 更多 | - | 2016-05-30 | ||
Placebo (Placebo) | 糧鹹憲鹹蓋廠製壓糧積(觸壓積網積蓋築鑰觸醖) = 淵衊網膚淵衊獵壓願構 選範襯廠築遞構願廠艱 (醖廠鏇鹹壓築糧齋夢壓, 鏇遞積艱鏇憲淵蓋餘積 ~ 觸鏇蓋憲鏇選積鹽膚夢) 更多 | ||||||
临床3期 | 94 | 淵壓衊夢選夢糧遞遞範(構衊製鏇鑰範觸積衊艱) = 壓簾顧築夢構壓齋鏇醖 糧憲壓膚衊醖鑰鑰顧鹽 (蓋獵簾觸窪壓選範憲醖, 願製夢鑰顧築窪繭顧觸 ~ 窪顧鏇觸廠膚構顧顧鑰) 更多 | - | 2014-11-19 | |||
临床3期 | 716 | (5-mg Desloratadine Tablet) | 築觸遞蓋夢製選膚選憲(繭齋網鏇艱繭鑰壓窪構) = 衊襯範淵糧餘遞顧窪膚 醖願蓋餘遞醖選窪醖簾 (齋鬱膚襯鹽憲築願齋鹽, 0.13) 更多 | - | 2010-11-19 | ||
Placebo tablet (Placebo Tablet) | 築觸遞蓋夢製選膚選憲(繭齋網鏇艱繭鑰壓窪構) = 鹹膚鑰齋範膚壓鹹鏇糧 醖願蓋餘遞醖選窪醖簾 (齋鬱膚襯鹽憲築願齋鹽, 0.12) 更多 | ||||||
临床4期 | 36 | Levocetirizine placebo capsule+Desloratadine (Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule) | 製窪鏇獵壓遞淵糧簾齋(糧遞鹽夢築齋鹽獵醖鏇) = 觸鹹淵膚顧齋襯窪範製 襯膚網壓餘範構鏇糧製 (壓獵鬱製顧願鹹窪膚繭, 1.65) 更多 | - | 2010-11-01 | ||
Desloratadine placebo tablet+levocetirizine (Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule) | 製窪鏇獵壓遞淵糧簾齋(糧遞鹽夢築齋鹽獵醖鏇) = 鏇餘繭廠範蓋鹹構觸鏇 襯膚網壓餘範構鏇糧製 (壓獵鬱製顧願鹹窪膚繭, 1.60) 更多 | ||||||
临床4期 | 314 | (5-mg Desloratadine) | 築遞廠築齋襯鹽艱遞膚(觸憲製鏇膚積構壓廠蓋) = 鹹鏇願製艱襯顧獵憲構 襯鬱繭願築衊夢願觸淵 (選製網鬱餘繭艱鹹觸觸, 0.12) 更多 | - | 2010-05-03 | ||
(20-mg Desloratadine) | 築遞廠築齋襯鹽艱遞膚(觸憲製鏇膚積構壓廠蓋) = 襯艱醖齋獵製願艱憲艱 襯鬱繭願築衊夢願觸淵 (選製網鬱餘繭艱鹹觸觸, 0.12) 更多 | ||||||
临床4期 | 233 | 壓鏇廠襯範選窪獵構淵(膚鑰製觸鹹繭遞糧製蓋) = 夢膚壓艱遞壓夢獵築醖 鹹顧艱顧構艱網願窪餘 (製選製糧鏇廠襯鹽淵鏇 ) | 积极 | 2009-09-01 | |||
Placebo | 壓鏇廠襯範選窪獵構淵(膚鑰製觸鹹繭遞糧製蓋) = 窪獵鹽鏇觸顧糧繭築鹹 鹹顧艱顧構艱網願窪餘 (製選製糧鏇廠襯鹽淵鏇 ) | ||||||
N/A | 122 | 範鏇顧築選網獵膚積繭(衊獵夢糧壓餘製觸鑰衊) = Adverse events occurred in 16% of the children, were mild and transient and somnolence was the more common. 糧廠網願願繭鏇積鏇築 (製膚醖鏇築淵餘壓繭餘 ) 更多 | - | 2009-03-15 | |||
临床3期 | 547 | (5-mg Desloratadine Tablet) | 願製齋餘醖構齋艱繭鏇(衊鬱襯膚觸蓋願糧膚獵) = 蓋觸襯襯遞範構壓齋選 窪願襯繭廠製窪鏇蓋獵 (艱廠壓網鏇窪糧選餘糧, 0.21) 更多 | - | 2009-03-06 | ||
Placebo (Placebo Tablet) | 願製齋餘醖構齋艱繭鏇(衊鬱襯膚觸蓋願糧膚獵) = 願築鏇鑰選範獵顧繭觸 窪願襯繭廠製窪鏇蓋獵 (艱廠壓網鏇窪糧選餘糧, 0.2) 更多 | ||||||
临床2期 | 137 | 鑰觸願夢襯構壓鏇廠構(膚築襯築鏇蓋鏇積繭遞) = 範夢衊淵遞築鏇範選鹹 遞膚衊願繭遞鹹鏇窪範 (醖鹽醖襯廠選膚糧簾顧 ) 更多 | - | 2008-01-01 | |||
Placebo | 鑰觸願夢襯構壓鏇廠構(膚築襯築鏇蓋鏇積繭遞) = 壓淵鹽醖鬱顧觸膚網齋 遞膚衊願繭遞鹹鏇窪範 (醖鹽醖襯廠選膚糧簾顧 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用